Anixa Biosciences, Inc. reports biotechnology developments tied to the treatment and prevention of cancer. The company's recurring news centers on its investigational breast cancer vaccine, developed with Cleveland Clinic and based on an α-lactalbumin immune-targeting approach, and liraltagene autoleucel, or lira-cel, an FSHR-targeted CAR-T therapy for recurrent ovarian cancer.
Company updates also cover clinical-trial observations, scientific conference presentations, intellectual-property protection for vaccine technology, manufacturing arrangements for clinical materials, and management presentations describing Anixa's oncology pipeline and business model.
Anixa Biosciences (NASDAQ: ANIX) is set to participate in two significant investor conferences: the LifeSci Partners 11th Annual Corporate Access Event on January 5-7, 2022, and the H.C. Wainwright BioConnect Conference from January 10-13, 2022. CEO Dr. Amit Kumar will address a panel on cancer vaccines on January 7 at 2:00 pm ET. Investors can request 1x1 meetings during both events. Anixa is focused on innovative cancer therapies and COVID-19 treatments, including a vaccine for triple negative breast cancer (TNBC).
Anixa Biosciences (NASDAQ: ANIX) has partnered with MolGenie to analyze compounds aimed at treating COVID-19. Recent findings suggest these compounds could be effective against the Omicron and Delta variants of SARS-CoV-2. The focus is on developing inexpensive, orally-administered therapies that can inhibit the virus’s main protease (Mpro). The compounds have shown promising efficacy and potency in initial testing. Anixa continues to adapt its strategy in response to emerging COVID-19 variants to support global health efforts.
Anixa Biosciences (NASDAQ: ANIX) has started dosing patients in a Phase 1 study of a vaccine aimed at preventing triple-negative breast cancer, a particularly aggressive cancer type. Conducted in partnership with Cleveland Clinic, the study is funded by the U.S. Department of Defense and will involve 18 to 24 patients at high risk for recurrence. Participants will receive three doses of the vaccine over six weeks. The study aims to assess the maximum tolerated dose and immune response, with completion expected by Q3 2022. The vaccine uses a unique approach targeting specific proteins associated with breast cancer.
Anixa Biosciences (NASDAQ: ANIX) has received a patent from the China National Intellectual Property Administration (CNIPA) for its Chimeric Antigen Receptor-T cell (CAR-T) technology, known as Chimeric Endocrine Receptor T-cell (CER-T) therapy. This innovation targets the follicle stimulating hormone receptor and is aimed at treating ovarian cancer. The technology has also received a Notice of Allowance from the U.S. Patent and Trademark Office. Clinical trials are expected to commence by year-end, with potential applications for other solid tumors as well.
Anixa Biosciences, Inc. (NASDAQ: ANIX) announced the U.S. Patent and Trademark Office granted a Notice of Allowance for its Chimeric Antigen Receptor-T cell (CAR-T) cancer treatment technology. The patent broadens protection for the company’s Chimeric Endocrine Receptor T-cell (CER-T) technology, specifically targeting ovarian cancer, with plans to start clinical trials before year-end. This technology, in collaboration with Moffitt Cancer Center and licensed from The Wistar Institute, holds potential for treating other solid tumors by exploiting unique hormone receptor biology.
Anixa Biosciences (NASDAQ: ANIX) announced that Dr. José Conejo-Garcia will present on September 23, 2021, at the Emerging Immunotherapeutics for Ovarian Cancer Symposium. He will discuss the FSHR-mediated CAR-T technology for ovarian cancer, which recently received FDA authorization for Phase 1 clinical trials. This technology aims to improve treatment outcomes by targeting the follicle stimulating hormone receptor on ovarian granulosa cells. Anixa holds exclusive rights to this innovative therapy, highlighting its potential to shift the treatment paradigm in ovarian cancer.
Anixa Biosciences, Inc. (NASDAQ: ANIX) will have its CEO, Dr. Amit Kumar, present at the virtual H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. Dr. Kumar will share insights on recent achievements, including FDA clearance for clinical trials of a CAR-T based ovarian cancer therapy and updates on breast cancer vaccine trials. Online one-on-one meetings will be available post-presentation. The event begins at 7:00 a.m. ET on September 13, 2021, with a webcast link provided for access.
Anixa Biosciences, Inc. (NASDAQ: ANIX) announced the appointment of Dr. Pamela D. Garzone as Chief Development Officer on September 7, 2021. Dr. Garzone, who has over 25 years of experience in the pharmaceutical industry, will oversee the company's vaccine and therapeutic development programs. Her role is particularly significant as Anixa prepares to enter clinical trials for its preventative breast cancer vaccine and ovarian cancer CAR-T treatment. CEO Amit Kumar expressed confidence in Dr. Garzone's leadership during this pivotal transition from pre-clinical to clinical phases.
Anixa Biosciences, Inc. (NASDAQ: ANIX) announced that its compounds may be more effective against the Delta variant of SARS-CoV-2 than the original strain. This follows a genomic variant analysis indicating stronger inhibition potential of the Mpro enzyme, crucial for viral replication. The need for affordable, stable, orally bioavailable COVID-19 treatments is emphasized due to vaccination limitations and variant efficacy concerns. The collaboration with MolGenie focuses on developing novel small molecule inhibitors, with ongoing synthesis of candidate compounds for pre-clinical testing.
Anixa Biosciences (NASDAQ: ANIX) announced the appointment of Director Dr. Arnold Baskies to the World Health Organization's Global Breast Cancer Initiative on August 23, 2021. Dr. Baskies, a seasoned surgical oncologist with extensive experience in cancer treatment, aims to strengthen global breast cancer efforts. Anixa is also developing a breast cancer vaccine in partnership with the Cleveland Clinic and the U.S. Department of Defense, which is set to enter clinical testing soon. This initiative aligns with Anixa's mission to combat cancer through innovative therapeutics.